Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro. - Wikidata - awgldk - TriplyDB

Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.

Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.

http://www.wikidata.org/entity/Q37030376

about

Combination treatment including targeted therapy for advanced hepatocellular carcinoma Update: the status of clinical trials with kinase inhibitors in thyroid cancer Advanced medullary thyroid cancer: pathophysiology and management Molecular-targeted agents combination therapy for cancer: developments and potentials.Sorafenib and thyroid cancer.Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases.Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities.Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature.Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells.Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one?A biomaterial screening approach reveals microenvironmental mechanisms of drug resistance.Recent advances in the biology and therapy of medullary thyroid carcinoma.A whole-animal platform to advance a clinical kinase inhibitor into new disease space.Sorafenib in the treatment of thyroid cancer.Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.

P2860

Q28077738-A83FCDB2-DD54-4EB4-BECF-F9F9316DB92B Q33570056-9AA09BAA-6A03-4F0B-B357-4307D001EEA0 Q36857218-D2C591D6-44EC-4DA1-A602-CAFFE355A315 Q38104670-C531081B-DD41-4263-82C6-7978E38A7CBA Q38118647-5CB84613-7C2D-47A3-A173-CC1EF5661117 Q38683133-750908C6-2683-430C-9DAA-1D755E175806 Q38733117-BC68D0FF-CDD5-43FC-ABBC-CFB75EF82F2B Q38813996-68316658-25E0-4CDD-B869-665089CA665B Q39130053-A21AA152-65DE-43BB-A887-9A12EDEA48FD Q41867909-5E99805E-FB62-497E-A6EC-1E52509BBC1C Q47328841-24F4FACF-D9FB-4133-AB31-060636877E0A Q48246978-7D07D8D7-E433-48BE-A9D2-BB7F23751A9E Q49884409-1A9B46CC-8FDD-4788-978E-77F93C08E46B Q55053748-2C97ED14-AD73-405A-8203-A8EB2CA9B7C5 Q55086907-88FFAD90-6535-4843-AEC9-C3731B4FDAF8

P2860

Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.

http://www.wikidata.org/entity/Q37030376

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 January 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.

@en

Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.

@nl

type

label

Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.

@en

Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.

@nl

prefLabel

Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.

@en

Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.

@nl

P1433

Q37030376-70C6D97A-50B2-417E-A2E5-FFCF1D4C70EB

P1476

Q37030376-D4413596-A906-44DB-A4B2-38B340DDE4D5

P2093

Q37030376-3602C5D0-258E-4B13-BAE8-25C7DDE2E520

Q37030376-536971F0-AFA8-431F-8D8C-8B5453AC0644

Q37030376-5996D13E-97A9-4A5E-AB23-DF401A099A98

Q37030376-69B01EE0-8544-4A43-89E1-D04728659154

Q37030376-6B3D0662-BAF5-468A-BA1E-BEE84CFB7622

Q37030376-70B6479C-089E-4E9B-B27C-A8B59719CE28

Q37030376-C962B79F-CF53-43A8-8E6B-D5B7020D7161

Q37030376-D88FC61A-484F-4898-B80C-2EF4AF88568C

Q37030376-E73C8CF4-C8C9-4769-811F-4EB0DD9D3915

P2860

Q37030376-0DFB5AAF-028C-4586-B668-B5977E9321FA

Q37030376-1DCE4163-360C-430F-B6EA-F39134FCA52E

Q37030376-23B9A67A-317F-4840-97E6-9C7BF461CF7C

Q37030376-3531349A-6845-4185-B20A-D95D80C3D390

Q37030376-4527C295-A8DB-432E-B438-A6B166455A4B

Q37030376-583C00B0-C87C-4F88-B1A5-3B2A3C614B64

Q37030376-592922DE-3B90-4F6A-9724-6C1770C20F85

Q37030376-5BA29B0E-793B-4CE0-83C1-214DF7406A04

Q37030376-5D9FD832-42B6-4B40-9320-8A53D9689DAC

Q37030376-5EFAC1F9-10DB-4128-B077-1FF708EA34F7

P304

Q37030376-8809BEA9-F394-4EE4-8021-EB4B86993795

P31

Q37030376-33E51A80-B980-46A0-B45B-50A5D81B060E

P356

Q37030376-D898DC5A-4E6D-4FFE-A0F9-4906E24EA811

P433

Q37030376-B7E703AB-6D3D-4E7B-AAFB-58420F2839CB

P478

Q37030376-CE647CA2-E6B7-4F38-B7BD-E9B176E97F08

P50

Q37030376-4F7EDA48-09BF-4805-A4F7-E4A0937950A8

Q37030376-E8F262B0-02EC-48E1-9B13-58E2B32C03EB

P577

Q37030376-35A8CA7B-9358-4A6B-A248-1ED81A5CB49C

P698

Q37030376-77401FB4-FED4-44F2-B2A3-6A2D58345B8B

P932

Q37030376-4849D76A-7380-4743-87CD-E188798963A2

P356

P1433

Endocrine-related cancer

P1476

Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro

@en

P2093

Chaojie Wang

http://www.w3.org/2001/XMLSchema#string

David Jarjoura

http://www.w3.org/2001/XMLSchema#string

Kitty Agarwal

http://www.w3.org/2001/XMLSchema#string

Manisha H Shah

http://www.w3.org/2001/XMLSchema#string

Matthew D Ringel

http://www.w3.org/2001/XMLSchema#string

Motoyasu Saji

http://www.w3.org/2001/XMLSchema#string

Samantha K McCarty

http://www.w3.org/2001/XMLSchema#string

Victoria J Brendel

http://www.w3.org/2001/XMLSchema#string

Yoon Woo Koh

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

BAY 43-9006 inhibition of oncogenic RET mutants.

Restraining PI3K: mTOR signalling goes back to the membrane.

Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model

Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer.

Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers.

P304

29-38

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1530/ERC-11-0155

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22109971

http://www.w3.org/2001/XMLSchema#string

P932

3717592

http://www.w3.org/2001/XMLSchema#string